Elusys Therapeutics reports results on anthrax anti-toxin studies

Elusys Therapeutics, a Pine Brook, New Jersey-based biopharmaceutical company, recently presented key findings from non-clinical studies evaluating the company's anthrax anti-toxin therapy at a conference in Victoria, British Columbia.

The company presented the results of studies on ETI-204, also known as Anthim, at the International Conference on Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis on September 5. Elusys presented the results of a pharmacokinetic study to determine a dosage amount for ETI-204, data from animal studies combining ETI-204 with antibiotic therapy and data on the survival and detection of anthrax antibodies in animals after receiving ETI-204.

"We are very encouraged with the data presented this week demonstrating the ability of ETI-204 to improve survival in rabbits at multiple dose levels and suggesting the potential for ETI-204 to reduce toxemia resulting from challenge with B. anthracis infection," Elizabeth Posillico, the president and CEO of Elusys, said. "ETI-204 is being evaluated in both (intravenous) and (intramuscular) routes of administration, and continues to show promise for the treatment of inhalational anthrax infection."

The studies found that rabbits receiving ETI-204 in combination with levofloxacin for three days were more likely to survive than rabbits taking levofloxacin alone or the control group. One rabbit study found that animals treated with ETI-204, levofloxacin or a combination of the two after being exposed to and surviving anthrax infection developed their own neutralizing anti-anthrax antibodies when re-exposed to anthrax.

ETI-204 is a monoclonal antibody targeting the protective antigen of B. anthracis that neutralizes the deadly effects of anthrax toxins by binding to the protective antigen.

Anthrax is a life-threatening disease caused by the Bacillus anthracis bacterium. Inhaled anthrax is often fatal despite treatment with antibiotics.